Primary Immunodeficiency Disorders News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Can the immune system be boosted? - Medical News Today



Medical News Today
 
Can the immune system be boosted? 
Medical News Today
Prolonged fasting has been linked with stem cell regeneration of older and damaged immune cells. Curcumin, found in curry and turmeric, may assist the immune system with clearing the brain of beta-amyloid plaques seen in Alzheimer's disease. High fat ...

 


ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive



ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... 
Market Exclusive
... operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are ...

and more » 


Help Others by Giving Blood - Magazine of Santa Clarita (blog)



Magazine of Santa Clarita (blog)
 
Help Others by Giving Blood 
Magazine of Santa Clarita (blog)
Violet and Ian have both been diagnosed with a Primary Immunodeficiency Disease which requires the two to receive an intravenous immunoglobulin (IVIG) infusion into the blood every other week. Due to their frequent recurrence of chronic infections ...

 


FDA Puts Clinical Holds on Trials of BPX-501 - OncLive



OncLive
 
FDA Puts Clinical Holds on Trials of BPX-501 
OncLive
In that study, investigators evaluated immune recovery and outcomes of 112 pediatric patients who underwent a haplo-HSCT followed by treatment with BPX-501. Children in the study had acute leukemia (n = 53), primary immune deficiencies (n = 26 ...
FDA hits Bellicum with clinical hold after brain damage cases in T-cell therapy trial FierceBiotech

all 9 news articles » 


Column: A looming nightmare for Wisconsin's Medicare patients - Green Bay Press Gazette



Green Bay Press Gazette
 
Column: A looming nightmare for Wisconsin's Medicare patients 
Green Bay Press Gazette
Imagine a scenario where your aging relative has primary immune deficiency disorder and needs an infused drug to ensure that their immune system fights off infection and other diseases. Now imagine the same scenario where you are told that Medicare ...

and more » 


Proper treatment of herpes zoster is 'a work in progress' - Philippine Star



Proper treatment of herpes zoster is 'a work in progress' 
Philippine Star
The zoster vaccine is currently indicated in patients aged 60 years and older, but since it is a live attenuated vaccine, it is contraindicated in many patients who could benefit most from it, including those with primary immunodeficiency disorders ...

and more » 


Backed by Numerous Lobbyists Plasma Protein Therapeutics Market to Sour New Highs During the Forecast Period of ... - Digital Journal



The Daily Telescope
 
Backed by Numerous Lobbyists Plasma Protein Therapeutics Market to Sour New Highs During the Forecast Period of ... 
Digital Journal
The report "Plasma Protein Therapeutics Market, by Product Type (Immunoglobulins, Albumin, Coagulation Factors, Alpha-1 Proteinase Inhibitor and Others), by Application (Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura ...
Backed by Numerous Lobbyists Plasma Protein Therapeutics ... The Daily Telescope

all 1 news articles » 


AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American ... - PR Newswire (press release)



AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American ... 
PR Newswire (press release)
Discovered and developed by AbbVie, upadacitinib is an investigational oral agent engineered to selectively inhibit JAK1, which plays an important role in the pathophysiology of immune-mediated disorders.2,3 Phase 3 trials of upadacitinib in rheumatoid ...

and more » 


Results from Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential for New BCG Revaccination Strategies ... - PR Newswire (press release)



Results from Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential for New BCG Revaccination Strategies ... 
PR Newswire (press release)
Introduced in 1921, BCG is the only vaccine currently licensed to prevent TB disease. Past observational studies have indicated that primary BCG vaccination may offer partial protection against initial Mtb infection. It has also been hypothesized that ...

and more » 


Learn Why Mitchell Blutt's Consonance Capital Management Lp Purchased Adma Biologics, Inc Stake? - BZ Weekly



BZ Weekly
 
Learn Why Mitchell Blutt's Consonance Capital Management Lp Purchased Adma Biologics, Inc Stake? 
BZ Weekly
Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused ...

and more »